Key facts
- Avayl’s last known valuation is $950K (Jan 2023).
- It has raised $100K; the latest was Early Stage VC in Jan 2025.
- Notable investors include Creative Destruction Lab, Entrepreneurs First, SquareOne Venture Capital, another.vc.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Avayl
- ·The full record, as it builds
Funding rounds
No funding rounds for Avayl are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Avayl
Developer of artificial intelligence-based data intelligence software designed to automate portfolio analysis and optimization in pharma and life science. The company's platform uses machine learning for predictive analysis and leverages competitor, regulatory, demand, and supply data, enabling pharma managers to focus on future opportunities and support important business decisions in the pharma industry.
- Sector
- Healthcare
- HQ
- Berlin, Germany
- Founded
- 2023
- Employees
- 14
- Website
- avayl.tech/
- Ownership
- Privately Held (backing)
Avayl doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Avayl shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Avayl in its N-PORT filings yet. We sweep new filings monthly.